ClinicalTrials.gg
Not yet recruitingNCT06249802BBLURANUpdated Feb 8, 2024

Beta-blockade in Unruptured Intracranial Aneurysm

A Phase 4 interventional study of Nebivolol and Placebo in Intracranial Aneurysm, sponsored by Jagiellonian University. Not yet recruiting at 1 site in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-08.

Sponsored by Jagiellonian University · Phase 4, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Intracranial Aneurysm with a site in Poland — 5 open to participants now, 6 under way, none of them phase 3. Intracranial Aneurysm · Poland.

Started
2025
with 1 other
Phase 4
Only one
of the 10
Registered
7th of 10
by date
Lead sponsor
1 of 10
Jagiellonian University

Among the 10 studies in Intracranial Aneurysm with a site in Poland, this one is one of 2 that started in 2025, is the only one in phase 4, and was the 7th registered.

Intracranial Aneurysm

419 studies on the registry are indexed under Intracranial Aneurysm; 118 are open to participants now.

Browse Intracranial Aneurysm studies →

Open to participants now

5 of the 10 studies in Intracranial Aneurysm with a site in Poland are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 84 Intracranial Aneurysm studies recruiting now, 50 (60%) set no upper age limit and 15 (18%) stop at 75 or younger; 16 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Intracranial Aneurysm with a site in Poland, or all of them as a file.
02

Study summary

Subarachnoid haemorrhage is a devastating type of stroke, with high mortality and morbidity rate. In approximately 85% of cases, it is caused by an intracranial aneurysm rupture. Majority of patients with diagnosed intracranial aneurysm are eligible for interventional treatment, however, some patients are managed conservatively. Currently, the only recommendations for patients with conservatively managed intracranial aneurysms, are routine imaging follow-ups and minimization of rupture risk factors. There are no medications proven to decrease risk of aneurysm rupture, that might be prescribed to such patients. In preliminary study the investigators found that patients with intracranial aneurysms who took β-blockers had significantly smaller aneurysm rupture rate and dome size, as well as more favorable hemodynamic parameters. No other antihypertensive drugs showed similar associations. Therefore, in this project the investigators aim to further analyze the impact of β-blocker intake on fate of intracranial aneurysm and find possible explanations for its protective role. The investigators aim to perform a randomised, double-blind, placebo-controlled clinical trial. One hundred patients with unruptured intracranial aneurysm, , qualified to conservative management will be enrolled. Two arms (50 patients each) will be receiving nebivolol or matching placebo. Treatment in each arm will last 12 months. The following examinations will be performed at baseline and at 6 and 12 months: clinical assessment, angio-MRI with vessel wall imaging, Doppler ultrasound to extract blood flow waveforms from Internal Carotid Artery, Vertebral Artery Middle Cerebral Artery, Anterior Cerebral Artery and Posterior Cerebral Artery, as well as blood samples. Based on the results the investigators will assess changes in aneurysm size and wall contrast enhancement. The investigators will also analyze levels of possible aneurysm growth biomarkers in peripheral blood. Additionally, the investigators will prepare three-dimensional models of the artery harbouring aneurysm and perform patient-specific computer modelling of blood flow through such artery to assess hemodynamic parameters of aneurysm dome. All obtained measurements will be compared at baseline and at 6 and 12 months. The investigators hypothesize that, in comparison to the placebo group, β-blocker therapy in patients with unruptured intracranial aneurysm will contribute to favorable changes in hemodynamic parameters of aneurysm dome, decrease wall degradation process and prevent from aneurysm growth.

03

Conditions studied

  • Intracranial Aneurysm

Browse trials for

Keywords

  • beta-blocker
  • intracranial aneurysm
  • rupture prevention
  • hemodynamic analysis
  • randomized clinical trial
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • freshly (within 12 months) diagnosed unruptured intracranial aneurysm, non-eligible for surgical or endovascular treatment
  • age > 18 years

Exclusion criteria

Exclusion Criteria:

  • to β-blockers intake
  • previous SAH
  • intake of β-blocker currently or in the past
  • presence of other intracranial pathology
  • history of surgical or endovascular aneurysm treatment
  • contraindications for contrast-enhancement MRI examination
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Nebivolol arm

    Patients randomly assigned to receive active treatment with escalating doses of nebivolol.

    Drug: Nebivolol

  • Placebo comparator
    Placebo arm

    Patients randomly assigned to receive matching placebo tablets.

    Drug: Placebo

Interventions

  • 12-month intake of medication

  • DrugPlacebo

    12-month intake of matching placebo

06

What researchers measure

Primary outcomes

  1. Intracranial aneurysm growth

    Any increase in size of intracranial aneurysm assessed by radiology specialist based on Magnetic Resonance Angiography.

    Time frame: 12 months

  2. Intracranial aneurysm rupture

    Fatal or non-fatal intracranial aneurysm rupture. Outcome will be determined based on presence of subarachnoid hemorrhage on head Computer Tomography (performed in case on any symptoms).

    Time frame: 12 months

Secondary outcomes

  1. All-cause mortality

    Death of any cause

    Time frame: 12 months

  2. Change in aneurysmal hemodynamic parameters

    5% increase or decrease (relative to measurement at baseline) of one or more following parameters: * dome fraction very high Oscillatory Shear Index (defined as percentage of aneurysm dome with Oscillatory Shear Index higher than 0.2) * dome fraction of very low Wall Shear Stress (defined as percentage of aneurysm dome with Wall Shear Stress lower than 0.5) * Surface Vortex Fraction (defined as as percentage of flow with positive Q-criterion in small layer near aneurysm wall) All parameters will be determined based on computer modelling of blood flow in aneurysm dome.

    Time frame: 12 months

  3. Change in aneurysm growth biomarkers

    Any change in serum levels of one or more biomarkers: IL-1,IL-6, IL-15, TGF- β and MCP-1.

    Time frame: 12 months

Other outcomes

  1. 5-year all-cause mortality, intracranial aneurysm rupture or necessity of neurosurgical intervention

    Yearly follow-up for all-cause mortality or intracranial aneurysm rupture or neurosurgical intervention

    Time frame: 5 years

07

Study locations

1 site
  • University Hospital in Krakow
    Kraków, Lesser Poland 30-688, Poland
    • Kornelia M Kliś, MD, PhD · Contactkornelia.klis@uj.edu.pl · +48 12 400 2450
    • Roger M Krzyżewski, MD, PhD · Contactroger.krzyzewski@uj.edu.pl · +48 12 400 2450
    • Kornelia M Kliś, MD, PhD · Principal investigator
    • Roger M Krzyżewski, MD, PhD · Principal investigator
    • Karolina Piotrowicz, MD, PhD · Sub investigator
    • Marcin P Surmiak, PhD · Sub investigator
    • Borys M Kwinta, MD, PhD · Sub investigator
    • Amira Bryll, MD, PhD · Sub investigator
    • Igor Szydłowski, MD · Principal investigator
    • Monika Ryś, MD · Sub investigator
    • Ian Perera, MD · Sub investigator
    • Jerzy Gąsowski, MD, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2025; primary completion for Jan 2029, 48 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2024
First posted
Feb 8, 2024
StartEst.
Jan 1, 2025
Primary completionEst.
Jan 1, 2029
CompletionEst.
Jan 1, 2030
Last update
Feb 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06249802
Collaborators
University Hospital in Krakow
Responsible party
Jerzy Gąsowski (Prof., Jagiellonian University) — Principal investigator
First posted
Feb 8, 2024
Start date
Jan 1, 2025 (estimated)
Primary completion
Jan 1, 2029 (estimated)
Completion
Jan 1, 2030 (estimated)
Last update
Feb 8, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nebivolol

Start the discussion